Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Diéras

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Oncology (Williston Park, N.Y.)|August 1, 1997
Review of docetaxel/doxorubicin combination in metastatic breast cancerV Diéras
Oncology (Williston Park, N.Y.)|June 1, 1997
Docetaxel in combination with doxorubicin: a phase I dose-finding studyV Diéras
British Journal of Cancer|December 9, 2003
The taxanes: toxicity and quality of life considerations in advanced ovarian cancerJ P Guastalla, V Diéras
Breast Cancer Research and Treatment|February 25, 2014
Expert perspectives on biosimilar monoclonal antibodies in breast cancerJ Cortés, G Curigliano, V Diéras
Therapie|June 22, 2000
[Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer]J P Martin, V Diéras, G Berdeaux
Oncology|November 6, 2001
Interaction between Herceptin and taxanesV Diéras, P Beuzeboc, V Laurence, et al.
British Journal of Cancer|January 28, 2012
Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agentsC Le Tourneau, V Servois, V Diéras, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Docetaxel in combination with doxorubicin or vinorelbineV Diéras, P Fumoleau, S Kalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2013
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patientsD W Miles, V Diéras, J Cortés, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 29, 2017
Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicityZ Ajgal, S de Percin, V Diéras, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Oncology (Williston Park, N.Y.)|August 1, 1997
Review of docetaxel/doxorubicin combination in metastatic breast cancerV Diéras
Oncology (Williston Park, N.Y.)|June 1, 1997
Docetaxel in combination with doxorubicin: a phase I dose-finding studyV Diéras
British Journal of Cancer|December 9, 2003
The taxanes: toxicity and quality of life considerations in advanced ovarian cancerJ P Guastalla, V Diéras
Breast Cancer Research and Treatment|February 25, 2014
Expert perspectives on biosimilar monoclonal antibodies in breast cancerJ Cortés, G Curigliano, V Diéras
Therapie|June 22, 2000
[Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer]J P Martin, V Diéras, G Berdeaux
Oncology|November 6, 2001
Interaction between Herceptin and taxanesV Diéras, P Beuzeboc, V Laurence, et al.
British Journal of Cancer|January 28, 2012
Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agentsC Le Tourneau, V Servois, V Diéras, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Docetaxel in combination with doxorubicin or vinorelbineV Diéras, P Fumoleau, S Kalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 30, 2013
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patientsD W Miles, V Diéras, J Cortés, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 29, 2017
Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicityZ Ajgal, S de Percin, V Diéras, et al.
Pageof 6